Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs

K J Lin; S Schneeweiss

doi:10.1002/cpt.359

Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs

Clin Pharmacol Ther. 2016 Aug;100(2):147-59. doi: 10.1002/cpt.359. Epub 2016 May 12.

Authors

K J Lin^{1

2

3}, S Schneeweiss^{1

3}

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
³ Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.

PMID: 26916672
DOI: 10.1002/cpt.359

Abstract

Health insurance claims and electronic health records (EHR) databases have been considered the preferred data sources with which to study drug safety and effectiveness in routine care. Linking claims data to EHR allows researchers to leverage the complementary advantages of each data source to enhance study validity. We propose a framework to evaluate the need for supplementing claims data with EHR and vice versa to optimize outcome ascertainment, exposure assessment, and confounding adjustment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Adverse Drug Reaction Reporting Systems / statistics & numerical data
Databases, Factual / statistics & numerical data*
Drug-Related Side Effects and Adverse Reactions / epidemiology
Electronic Health Records / statistics & numerical data*
Humans
Insurance, Health / statistics & numerical data
Medical Record Linkage / methods*
Pharmaceutical Preparations / administration & dosage

Substances

Pharmaceutical Preparations